Vaccine-Preventable Transmission Diseases

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines and Public Health".

Deadline for manuscript submissions: 31 August 2026 | Viewed by 1730

Special Issue Editors


E-Mail Website
Guest Editor
Food Hygiene and Nutrition Service, Azienda Sociosanitaria Ligure 3, Genoa, Italy
Interests: vaccine; prevention; epidemiology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Vaccination is recognized as one of the best strategies to increase duration and quality of life over the last centuries. The implementation of surveillance systems has enhanced the understanding of vaccine-preventable diseases and promoted the use of preventive strategies. This Special Issue aims to contribute to the literature and data on transmission routes, findings on high-risk groups for vaccine-preventable diseases, effectiveness and safety of vaccination, and strategies that could contribute to improving vaccination coverage.

Articles on vaccine-preventable diseases affecting infants, adolescents, adults, the elderly, at-risk populations (due to comorbidities and personal risk factors), healthcare workers, and strategies to promote vaccination adherence among these categories are welcome. This Special Issue encourages the submission of original articles, systematic reviews or meta-analyses, short communications, and other types of articles that can improve knowledge on vaccine-preventable diseases and related topics.

Prof. Dr. Vincenzo Restivo
Dr. Cecilia Trucchi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • vaccine-preventable diseases
  • transmission route
  • high-risk people
  • vaccination
  • vaccine effectiveness
  • vaccination safety
  • neonatal immunization
  • adult vaccination
  • elderly vaccination

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

14 pages, 2269 KB  
Article
Real-World Vaccination Data Analysis for Three Vaccines Among Individuals Aged 60 and Older in Shanghai, China
by Juan Li, Mingzhu Lin, Yong Feng, Wanran Cheng, Cuiping Zhou, Shaotan Xiao, Pengfei Deng and Laibao Yang
Vaccines 2026, 14(3), 246; https://doi.org/10.3390/vaccines14030246 - 7 Mar 2026
Viewed by 1120
Abstract
Background: Vaccines targeting herpes zoster, influenza, and pneumococcal diseases represent the most effective interventions for reducing morbidity and mortality in individuals aged ≥65 years. This study employs real-world vaccination data for herpes zoster vaccine (HZV), influenza vaccine (InfV), and 23-valent pneumococcal polysaccharide [...] Read more.
Background: Vaccines targeting herpes zoster, influenza, and pneumococcal diseases represent the most effective interventions for reducing morbidity and mortality in individuals aged ≥65 years. This study employs real-world vaccination data for herpes zoster vaccine (HZV), influenza vaccine (InfV), and 23-valent pneumococcal polysaccharide vaccine (PPSV23) among individuals aged ≥60 years in the Pudong New Area of Shanghai, China, from 2020 to 2024, aiming to assess the vaccination coverage for the three vaccines. Methods: Demographic data and vaccination records for HZV, InfV, and PPSV23 were obtained from the Shanghai Immunization Information System. Vaccination coverage, temporal trends, and disparities across different demographic groups and subdistricts or towns were analyzed. Results: From 2020 to 2024, a total of 26,227 doses of HZV, 198,373 doses of InfV, and 102,644 doses of PPSV23 were administered to adults aged ≥60 years in the Pudong New Area of Shanghai, with vaccination coverage of 0.23%, 3.12%, and 1.61%, respectively. HZV coverage peaked in 2023 (0.34%), whereas the highest coverage for InfV (3.94%) and PPSV23 (3.21%) occurred in 2020. The highest vaccination coverage was observed in the 70–74 age group for HZV (0.30%), the 75–79 age group for InfV (5.18%), and the 65–69 age group for PPSV23 (2.15%). Coverage for HZV and InfV was higher among females than males, while PPSV23 coverage was higher among males. Individuals with local household registration had significantly higher coverage for all three vaccines compared to those with non-local registration. The subdistricts or towns with the highest HZV coverage were Jinqiao Town (0.59%), Huamu Subdistrict (0.50%), and Lujiazui Subdistrict (0.34%). For InfV, the highest coverage was observed in Tangqiao Subdistrict (5.50%), Huamu Subdistrict (5.46%), and Lujiazui Subdistrict (4.88%). For PPSV23, the top three were Laogang Town (2.79%), Nicheng Town (2.01%), and Datuan Town (1.93%). Significant spatial clustering was observed for HZV and InfV. Conclusions: Vaccination coverage for HZV, InfV, and PPSV23 among adults aged ≥60 years in the Pudong New Area of Shanghai from 2020 to 2024 was generally low, with evident temporal variations and demographic and spatial disparities. Coverage differed by age group, gender, household registration status, and subdistricts or towns. These findings indicate that future interventions are still needed to increase vaccination coverage among older adults. Full article
(This article belongs to the Special Issue Vaccine-Preventable Transmission Diseases)
Show Figures

Figure 1

Back to TopTop